Systemic Therapy in Recurrent or Metastatic Squamous 
Cell Head and Neck Cancer

Jeremic, Branislav; Ozyigit, Gokhan; Kiladze, Ivane; Filipovic, Nenad; Dubinsky, Pavol

doi:10.5505/tjo.2021.2849

Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Ivane KILADZE, (Caucasus Medical Center, Department of Clinical Oncology, Georgia)

Gökhan ÖZYİĞİT, (Hacettepe Üniversitesi, Radyasyon Onkolojisi Anabilim Dalı, Ankara, Türkiye)

Pavol DUBINSKY, (East Slovakia Institute of Oncology, Department of Radiation Oncology, Slovakia)

Nenad FILIPOVI, (Center for Biomedical Engineering, Department of Oncology, Serbia)

Branislav JEREMI (University of Kragujevac, Faculty of Medicine, Serbia)

Türk Onkoloji Dergisi

0 0

Yıl: 2021 Cilt: 36 Sayı: 4 Sayfa Aralığı: 519 - 528 Metin Dili: İngilizce DOI: 10.5505/tjo.2021.2849 İndeks Tarihi: 15-06-2022

Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Öz:

Squamous cell head and neck cancer (SCHNC) is the seventh most common cancer worldwide. Most of SCHNC are locally advanced at diagnosis and are treated with combination of surgery and/or radiotherapy with chemotherapy. In spite of aggressive treatment, many patients relapse within the 3 years following the diagnosis. Those whose tumor cannot be resected or reirradiated are treated with a systemic treatment mostly in a palliative setting. They are identified as recurrent and/or metastatic SCHNC (R/MSCHNC) patients. First-line treatment of R/M-SCHNC historically consisted of cytotoxic agents such as methotrexate, bleomycin, or platinum-based protocols until targeted biological therapies were introduced in the 2000’s. The recent years witnessed a shift in systemic treatment toward the use of monoclonal antibodies and tyrosine kinase inhibitors, largely based on recent understanding of the role of immune dysfunction in SCHNC. Our review focuses on recent developments of molecular-targeted and immunotherapies in the treatment SCHNC, mostly focusing on R/M-SCHNC. It also highlights ongoing trials and discusses some promising novel targets in HNC, as well as clinical trial design challenges.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.
2. Pignon JP, le Maître A, Maillard E, Bourhis J, MACHNC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4–14.
3. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebrve JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350(19):1945–52.
4. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamouscell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–44.
5. Sacco AG, Cohen EE. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 2015;33(29):3305–13.
6. Ling DC, Bakkenist CJ, Ferris RL, Clump DA. Role of immunotherapy in head and neck cancer. Semin Radiat Oncol 2018;28(1):12–6.
7. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10(8):789–99.
8. Whiteside TL. Head and neck carcinoma immunotherapy: Facts and hopes. Clin Cancer Res 2018;24(1):6– 13.
9. Lau A, Yang WF, Li KY, Su YX. Systemic therapy in recurrent or metastatic head and neck squamous cell carcinoma a systematic review and meta-analysis. Crit Rev Oncol Hematol 2020;153:102984.
10.Jeremic B, Dubinsky P, Jeremic M, Kiladze I, Ozyigit G. Optimal dose of cisplatin (CDDP) given concurrently with radiotherapy (RT) in locally advanced squamous cell head and neck cancer (SQC HNC). Turk J Oncol 2020;35:237–41.
11.Jeremic B, Dubinsky P, Filipovic N, Ozyigit G. Optimal administration frequency of cisplatin concurrently with radical radiotherapy in the definitive treatment of locally advanced, inoperable squamous cell carcinoma of the head and neck. Still obscured by clouds? Turk J Oncol 2019;34:133–6.
12.Jeremic B, Ozyigit G, Dubinsky P, Filipovic N. Importance of HPV positivity in squamous cell head and neck cancer. Turk J Oncol 2019;34(3):204–14.
13.Jeremic B, Ozyigit G, Jeremic M, Dubinsky P. Impact of radiotherapy fractionation on outcome in squamous cell head and neck cancer (SQC HNC). Turk J Oncol 2020;35(3):356–62.
14.Molin Y, Fayette J. Current chemotherapies for recurrent/metastatic head and neck cancer. Anticancer Drugs 2011;22(7):621–5.
15.Hoffmann TK. Systemic therapy strategies for head- -neck carcinomas: Current status. GMS Curr Top Otorhinolaryngol Head Neck Surg 2012;11:Doc03.
16.Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012;13(1):35–46.
17.Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40(14):2071–6.
18.Pivot X, Awada A, Gedouin D, Kerger J, Rolland F, Cupissol D, et al. Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer. Ann Oncol 2003;14(3):373–7.
19.Vermorken JB. Randomized phase II trial of weekly methotrexate versus two schedules of three-weekly paclitaxel (Taxol®) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1999;18:395a.
20.Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. J Clin Oncol 1994;5(6):521–6.
21.Jacobs C, Lyman G, Velez-Garcai E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–63.
22.Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350–6.
23.Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171–7.
24.Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27(11):1864–71.
25.Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–27.
26.Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2021;22(4):463–75.
27.Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, et al. SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial. Lancet Oncol 2013;14(8):697–710.
28.Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, et al. Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2019;37(34):3266–74.
29.Ehrlich P. Uber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909;5(2):273–90.
30.Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget 2014;5(24):12472–508.
31.Tosoni A, Franceschi E, Pasquini E, Lanese A, Donini E, Foschini MP, et al. Immunotherapy in head and neck cancer: evidence and perspectives. Immunotherapy 2017;9(16):1351–8.
32.Machiels JP, Leemans CR, Golusinski W, Grau C, Licitra L, Gregoire V, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(11):1462–75.
33.Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17(7):956–65.
34.Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/ or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34(32):3838–45.
35.Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. J Clin Oncol 2017;35(14):1542–9.
36.Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr., et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915–28.
37.Szturz P, Vermorken JB. Further clinical interpretation and implications of KEYNOTE-048 findings. Lancet 2020;396(10248):378–9.
38.Cohen EE, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67.
39.Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67.
40.Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PDL1 expression. Oral Oncol 2018;81:45–51.
41.Segal NH, Ou SI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: Results from a phase I/II expansion cohort. Eur J Cancer 2019;109:54–161.
42.Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer 2019;107:142–52.
43.Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, et al. Safety and clinical activity of atezolizumab in head and neck cancer: Results from a phase I trial. Ann Oncol 2018;29(11):2247–53.
44.Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol 2020;31(7):942–50.
45.Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/ negative recurrent or metastatic HNSCC: The phase 2 CONDOR randomized clinical trial. JAMA Oncol 2019;5(2):195–203.
46.Kao HF, Ang MK, Ng QS, Tan DS, Tan W, Rajasekaran T, et al. Combination Ipilimumab and Nivolumab in Recurrent/Metastatic Nasopharyngeal Carcinoma (R/M NPC) Updated Efficacy and Safety Analysis of NCT03097939. ESMO Asia Virtual Congress; 2020.
47.Ruzsa A, Sen M, Evans M, Lee LW, Hideghety K, Rottey KS, et al. Phase 2, open-label, 1:1 Randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Invest New Drugs 2014;32(6):1278–84.
48.Chow LQ, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, et al. Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN. Clin Cancer Res 2016;23(10):2442–50.
49.Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, et al. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: The active 8 randomized clinical trial. JAMA Oncol 2018;4(11):1583–8.
50.Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): A randomised, double blind, placebo-controlled phase 2 trial. Lancet. Oncol 2017;18(3):323–35.
51.Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, et al. Phase II trial of everolimus and erlotinib in patients with platinumresistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2015;26(7):1476–80.
52.Geiger JL, Bauman JE, Gibson MK, Gooding WE, Varadarajan P, Kotsakis A, et al. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head Neck 2016;38(12):1759–64.
53.Dunn LA, Fury MG, Xiao H, Baxi SS, Sherman EJ, Korte S, et al. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2017;28(10):2533–8.
54.Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM. Oncolytic virotherapy for head and neck cancer: Current research and future developments. Oncolytic Virotherapy 2015;4:83–93.
55.Blasco M, Svider P, Raza S, Jacobs JR, Folbe AJ, Saraf P, et al. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs. Laryngoscope 2017;127(11):2565–9.
56.Brockstein B, Vokes E. Treatment of Metastatic and Recurrent Head and Neck Cancer. In: UpToDate [Database on the Internet]. Altham, MA: UpToDate; 2020.
57.Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA, Eastern Cooperative Oncology Group. A randomized phase II study of ixabepilone (BMS247550) given daily 3 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: An Eastern cooperative oncology group study. Ann Oncol 2008;19(5):977–83.
58.Joshi A, Patil V, Noronha V, Dhumal S, Pande N, Chandrasekharan A, et al. Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. Oral Oncol 2017;75:54–60.
59.Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, et al. Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with platinumbased therapy. Oncologist 2016;21(12):e1416–7.
60.Pivot X, Wadler S, Kelly C, Ruxer R, Tortochaux J, Stern J, et al. Result of two randomized trials comparing nolatrexed (Thymitaq™) versus methotrexate in patients with recurrent head and neck cancer. Ann Oncol 2001;12(11):1595–9.
61.Fury M, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, et al. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw 2012;10(11):1391–8.
62.Ferrarotto R, William W, Tseng J, Marur S, Shin DM, Murphy B, et al. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 2018;82:83–90.
63.Argiris A, Ghebrenmichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern cooperative oncology group trial. J Clin Oncol 2013;31(11):1405–14.
64.Jimeno A, Bauman JE, Weissman C, Adkins D, Schnadig I, Beauregard P, et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol 2015;51(4):383–8.
65.Jimeno A, Shirai K, Choi M, Laskin J, Kochenderfer M, Spira A, et al. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann Oncol 2015;26(3):556–61.
66.Jin Z, Zhang B, Zhang L, Huang W, Mo X, Chen Q, et al. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis. Ther Adv Med Oncol 2020;12:1758835920983717.
67.Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82.
68.Kiaris H, Spandidos DA, Jones AS, Vaughan ED, Field JK. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 1995;72(1):123–8.
69.Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol 2021;39(17):1856–64.
70.Cox AD, Der CJ, Philips MR. Targeting RAS membrane association: Back to the future for anti-RAS drug discovery? Clin Cancer Res 2015;21(8):1819–27.

APA	Kiladze I, Ozyigit G, Dubinsky P, Filipovic N, Jeremic B (2021). Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. , 519 - 528. 10.5505/tjo.2021.2849
Chicago	Kiladze Ivane,Ozyigit Gokhan,Dubinsky Pavol,Filipovic Nenad,Jeremic Branislav Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. (2021): 519 - 528. 10.5505/tjo.2021.2849
MLA	Kiladze Ivane,Ozyigit Gokhan,Dubinsky Pavol,Filipovic Nenad,Jeremic Branislav Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. , 2021, ss.519 - 528. 10.5505/tjo.2021.2849
AMA	Kiladze I,Ozyigit G,Dubinsky P,Filipovic N,Jeremic B Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. . 2021; 519 - 528. 10.5505/tjo.2021.2849
Vancouver	Kiladze I,Ozyigit G,Dubinsky P,Filipovic N,Jeremic B Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. . 2021; 519 - 528. 10.5505/tjo.2021.2849
IEEE	Kiladze I,Ozyigit G,Dubinsky P,Filipovic N,Jeremic B "Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer." , ss.519 - 528, 2021. 10.5505/tjo.2021.2849
ISNAD	Kiladze, Ivane vd. "Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer". (2021), 519-528. https://doi.org/10.5505/tjo.2021.2849

APA	Kiladze I, Ozyigit G, Dubinsky P, Filipovic N, Jeremic B (2021). Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi, 36(4), 519 - 528. 10.5505/tjo.2021.2849
Chicago	Kiladze Ivane,Ozyigit Gokhan,Dubinsky Pavol,Filipovic Nenad,Jeremic Branislav Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi 36, no.4 (2021): 519 - 528. 10.5505/tjo.2021.2849
MLA	Kiladze Ivane,Ozyigit Gokhan,Dubinsky Pavol,Filipovic Nenad,Jeremic Branislav Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi, vol.36, no.4, 2021, ss.519 - 528. 10.5505/tjo.2021.2849
AMA	Kiladze I,Ozyigit G,Dubinsky P,Filipovic N,Jeremic B Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi. 2021; 36(4): 519 - 528. 10.5505/tjo.2021.2849
Vancouver	Kiladze I,Ozyigit G,Dubinsky P,Filipovic N,Jeremic B Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer. Türk Onkoloji Dergisi. 2021; 36(4): 519 - 528. 10.5505/tjo.2021.2849
IEEE	Kiladze I,Ozyigit G,Dubinsky P,Filipovic N,Jeremic B "Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer." Türk Onkoloji Dergisi, 36, ss.519 - 528, 2021. 10.5505/tjo.2021.2849
ISNAD	Kiladze, Ivane vd. "Systemic Therapy in Recurrent or Metastatic Squamous Cell Head and Neck Cancer". Türk Onkoloji Dergisi 36/4 (2021), 519-528. https://doi.org/10.5505/tjo.2021.2849